ClinicalTrials.gg
Not yet recruitingNCT07861165GAMAUpdated Oct 6, 2026

Gender Affirming Mastectomy Analgesia Rial

An interventional study of Paravertebral (single injection) and Wide local infiltration in Gender Affirming Surgery, Mastectomy and Acute Pain, sponsored by Nova Scotia Health Authority. Not yet recruiting at 1 site in Canada. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Nova Scotia Health Authority · Not applicable, Interventional, and Treatment

How we know

Updated Oct 6, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 61 studies in Acute Pain with a site in Canada — 8 open to participants now, 10 under way, 1 of them phase 3. Acute Pain · Canada.

Planned enrollment
34th of 54
64 · median 80
Started
2027
the only one that year
No phase
31 of 61
4 open now
Registered
61st of 61
by date

Among the 61 studies in Acute Pain with a site in Canada, this one is the 34th largest by planned enrollment of the 54 interventional ones that give a count, is the only one that started in 2027, is one of 31 with no phase, and was the 61st registered.

Acute Pain

1,077 studies on the registry are indexed under Acute Pain; 168 are open to participants now.

Browse Acute Pain studies →

Open to participants now

8 of the 61 studies in Acute Pain with a site in Canada are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 103 Acute Pain studies recruiting now, 40 (39%) set no upper age limit and 50 (49%) stop at 75 or younger; 21 take children under 18; 24 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies in Acute Pain with a site in Canada, or all of them as a file.
02

Study summary

Introduction:

Optimizing pain management after gender-affirming mastectomy (removal of breast tissue, aka top surgery) surgery is important for recovery and minimizing opioid use. While paravertebral nerve blocks (numbing the chest wall through injections near the spine) and injection of local anesthetic ("skin freezing") are two commonly used methods, it's not clear which of these techniques is best among patients seeking gender-affirming care. Previous studies on nerve blocks in breast surgery have mostly concentrated on patients having breast cancer removed. Studies show that paravertebral blocks are superior to skin freezing in breast cancer surgery. However, it has not been established whether this reduces long-term pain and works similarly in gender-affirming top surgery. This study aims to compare the how well nerve blocks work comparing to skin freezing for pain and opioid use after surgery.

Research question:

Does the use of paravertebral nerve blocks, as compared to skin freezing (aka wide local infiltration), reduce need for opioid use within the first 24 hours following gender-affirming mastectomy?

Hypothesis:

The investigators hypothesize that paravertebral nerve blocks are superior to wide local infiltration in terms of reduced need for opioid consumption in the first 24 postoperative hours for gender-affirming mastectomy (GAM) patients.

Methodology:

This randomized control trial will include adult patients undergoing GAM. The patients will be randomly placed into the either the nerve block group or the skin freezing group. Patients who are in the skin freezing group will also be sent to the block room where they will receive ultrasound and pressure to mimic the feeling of receiving a block. Pain will be measured using the 0-10 Numeric Rating Scale, and opioid use will be recorded at 24-, 48-, and 72-hours post-op. Given that most patient leave hospital on the same day, participants will complete a pain journal at home and will be emailed an electronic survey to submit their results. Quality of recovery will be measured at 3 days after surgery. A follow-up survey at 3 months will assess longer term pain using the Brief Pain Inventory. Phone calls to complete the survey with a member of the research team can be done by request.

Read the detailed description

In Canada, there has been a rise in the number of transgender and gender-diverse individuals seeking gender-affirming care in recent years. Canada has seen roughly a ten-fold increase in gender-affirming care referrals over the past decade.

A gender-affirming mastectomy (GAM), also called top surgery, is one potential intervention for trans men and non-binary individuals. This procedure entails bilateral mastectomy with chest contouring to create a masculine-appearing chest. This operation is life-changing for many as it can alleviate gender dysphoria and improve mental health and quality of life.

A significant clinical issue in GAM is postoperative pain management. These procedures involve large incisions across the chest and tissue excision, and as such, pain can be significant. With only a few other studies focused on our target population, evidence on effective pain management strategies in this population is limited, and many nerve block types have not been studied.

A wide body of research focuses on nerve block use for oncological mastectomies. Network metanalysis has recognized continuous paravertebral nerve blocks as the most effective regional anesthesia technique, while wound infiltration is only slightly better than no intervention. Oncological research recognizes the ability of continuous paravertebral nerve blocks to provide prolonged analgesia and decrease opioid consumption. That said, there are some concerns about directly applying this knowledge to individuals having a mastectomy due to gender-affirming purposes. Patients undergoing GAM are often young and healthy without comorbidities that many breast cancer patients have. Additionally, many breast cancer patients undergo axillary lymph node dissection, which can increase post-operative pain There is also research that indicates that chronic testosterone administration, which applies to much of this population, increases pain thresholds, which could have potential impacts on the analgesic requirements for these patients. Many seeking mastectomies due to gender-affirming purposes have a positive outlook on the operation in comparison to patients having a mastectomy due to breast cancer. This may alter their pain perception. Notably, some research indicates stressors, such as those caused by gender dysphoria, may exacerbate pain. These differences between the patient populations' pain profiles make this research necessary to better understand this supplemental analgesia technique in gender-affirming care.

Primary Study Objective The primary objective is to determine whether paravertebral nerve blocks are superior to wide local infiltration in terms of decreased opioid consumption (oral morphine equivalents) in the first 24 postoperative hours for people undergoing GAM.

Secondary Objectives

Determine whether paravertebral nerve blocks are superior to wide local infiltration after GAM for:

  • Average pain score in the first 24 hours
  • Time in Post Anesthesia Care Unit (PACU)
  • Postoperative nausea and vomiting (PONV) in PACU
  • Quality of Recovery (QoR-15) at 3 days
  • EuroQol five-dimensional questionnaire (EQ-5D) at 3 days and 3 months
  • Persistent postsurgical pain (brief pain inventory) at 3 months
  • Postoperative complications with first 7 postoperative days

Research questions RQ1: Does the use of paravertebral nerve blocks, as compared to wide local infiltration, reduce opioid consumption within the first 24 hours following gender-affirming mastectomy? RQ2: What is the trajectory of pain and opioid use in the 72 hours following gender-affirming mastectomy? RQ3: Does the use of paravertebral nerve blocks, as compared to wide local infiltration, improve other postoperative patient centered outcomes (pain at 24 hours, PONV, QoR-15, EQ-5D, long-term pain)?

Methods This study will include patients undergoing gender affirming bilateral mastectomy at the QEII Health Sciences Center in Halifax, Nova Scotia.

Number of participants The study will include a maximum of 64 participants, randomly assigned to 2 study arms of 32 participants (paravertebral or wide local infiltration). The patients will be consented and screened at least 1 day before their surgery.

Randomization and concealment Patients who have consented to the study, will be randomly assigned into two groups. A computer-generated online randomization software will be used to randomize patients on a 1:1 basis to the paravertebral block (PVB) or the wide local infiltration (WLI) groups. The patient will either receive a paravertebral nerve block by anesthesiology in the block room versus wide local infiltration by the surgeon. Patients randomized to the PVB group will receive the block as per protocol, while those in the WLI group will undergo simulated block procedures using ultrasound and applied pressure to mimic the experience. The study data will be analyzed as per intention-to-treat.

Standardized Anesthesia technique Intravenous access and monitors typical at our institution including peripheral intravenous cannula(s), temperature probe and standard Canadian Anesthesiologists' Society (CAS) monitors (electrocardiography, pulse oximeter, and non-invasive blood pressure) will be applied. Induction and maintenance medication will be left to the discretion of the attending anesthesiologist with some exceptions. Lidocaine infusions will not be permitted in study patients. These medications are rarely used intraoperatively in plastic surgery and may increase the risk of LAST if given near the time of a block. Opioid administration intraoperatively and postoperatively will be administered at the discretion of the treating team. Use of intravenous dexamethasone will be encouraged unless contraindicated.

Postoperative care The standard of care for pain management for this patient population is opioid based (fentanyl, morphine, hydromorphone) with acetaminophen. The opioid medications are ordered as intermittent doses either injected intravenously, subcutaneously or ingested orally in the PACU. Codeine prescriptions will not be permitted due to their inconsistent conversion to morphine.

Regardless of group allocation, patients will receive all the usual pain medications they normally would in the postoperative period.

Data collection procedure Baseline data

A research coordinator (RC) will collect the baseline data as outlined below at the time of recruitment to the study:

  • Age, sex assigned by birth, self-identified gender, body mass index (BMI), preoperative pain medication, comorbidities (respiratory disease, cardiac disease, kidney disease, liver disease, prior stroke, seizure disorders)
  • Pre-existing pain (Brief pain inventory)
  • Cannabis use within the last month on average (route (inhaled versus ingested), frequency, dose). Routine or high dose cannabis use is known to be associated with high postoperative pain scores.
  • American Society of Anesthesiologists' (ASA) classification.
  • Testosterone dosing and route (if applicable)

Postoperative data Participants will be provided with a journal to track their postoperative data. Then at 3 days, 7 days, and 3 months participants will be emailed a survey hosted on Research Electronic Data Capture (REDCap) to share their recovery.

Any patient that would prefer to have the surveys completed over the phone can request this and a member of the research team will call them on day 1, 2, 3, and 7; then 3 months post operatively. Survey responses can be stored in the patient's pain journal for questions that would have been asked at earlier timeframes (e.g., 24 hours) to match the data collected from the those completing the surveys online.

Statistical analysis Primary and secondary analyses Numerical outcomes from RQ1 and RQ3 will be tested using a Welch t-tests with condition as a predictor of various outcomes (24hr opioid use, 24hr pain, QoR-15, EQ-5D, and persistent pain at 3 months). The categorical outcome (PONV) will be analyzed using a chi-squared test of independence. Trajectories of pain and opioids over the first 72hrs (RQ2) will be analyzed using linear mixed models; the investigators will explore both linear and quadratic models for rates of change over time. Linear mixed models will be used in a similar fashion to assess trajectories of change in gender congruence at 4 time points (baseline, day 3, day 7, and 3 months).

In all cases, the investigators will include all patients as an intention-to-treat protocol, using data when it is available for each outcome (even if data is missing from other outcomes). To address missing data, multiple imputation will be used, as it is a gold standard method for handing missingness.

03

Conditions studied

  • Gender Affirming Surgery
  • Mastectomy
  • Acute Pain

Browse trials for

Keywords

  • gender affirming mastectomy
  • regional anesthesia
  • nerve block
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult (aged >18 years) patients
  • Undergoing gender affirming bilateral mastectomy
  • Self-identifying with gender dysphoria

Exclusion criteria

Exclusion Criteria:

  • Severe pre-existing liver disease (Child B or C)
  • Severe kidney disease ( (GFR) \<30 (mL/min/1·73m²))
  • Severe lung disease (modified Medical Research Council Dyspnea Scale > 2)
  • An allergy to ropivacaine
  • Weight \<50 kg
  • Unable to provide valid consent to study prior to surgery
  • >45

Justification for exclusion criteria Patients being excluded for liver disease, kidney disease, and low weight decreases the risk of local anesthetic systemic toxicity. Known allergy to ropivacaine (the local anesthetic used in both groups) is to avoid anaphylaxis or other serious allergic reaction. Both types of blocks have a low risk of pneumothorax (injury to the lung); hence excluding patients with severe lung disease. Higher BMI (due to excess adipose tissue) increases the difficulty of nerve blocks, which could both increase risks and decrease success rates. Inability to provide consent interferes with the consent process. While a caregiver could provide consent on behalf the patient, the patient would not be able to complete self-rated scores, which are the central outcomes of this study.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
64 participants (estimated)

Study arms

  • Active comparator
    Wide local infiltration (WLI)

    Local anesthetic placed by the surgeon

    Procedure: Wide local infiltration

  • Experimental
    Paravertebral (PVB)

    Paravertebral block placed by anesthesiologist under ultrasound

    Procedure: Paravertebral (single injection)

Interventions

  • ProcedureParavertebral (single injection)

    The regional anesthesiologist or fellow will place the paravertebral nerve block in the block room. The patient will be placed in prone position. Before any nerve block, a subcutaneous injection of lidocaine 1% is performed to numb the skin before insertion of the block needle. The block will be US-guided, using a 22g echogenic block needle to deliver a total of 20ml of ropivacaine 0.5% on each side into the paravertebral space. The paravertebral space will be identified by visualizing the transverse processes, the associated ribs, the costotransverse ligament, and observing pleural depression with injection of the local anesthetic. The level of the paravertebral block will be left to the discretion of the regional anesthesiologist (but T3-5 would be most common for anterior chest wall procedures).

  • ProcedureWide local infiltration

    Ropivacaine 0.5% is used for wide local infiltration anesthesia in the comparison group at the conclusion of the procedure. Forty ml are used in total, and approximately 5ml is injected bilaterally into each of the superomedial, superolateral (into the pectoralis major muscle fascia), inferolateral (over the drain site), and inferomedial.

06

What researchers measure

Primary outcomes

  1. Opioid consumption

    Total opioid consumption (converted to oral morphine equivalents)

    Time frame: 24 hours

Secondary outcomes

  1. Average pain score

    Average pain score using the numerical rating scale (NRS) rated on a 0-10 scale with 0 being no pain and 10 being the worse pain imaginable.

    Time frame: 24 hours

  2. Time in Post Anesthesia Care Unit (PACU)

    Time in Post Anesthesia Care Unit (PACU) measured in minutes

    Time frame: Time in PACU is measured from the patient entering the PACU until they are discharged to home or the hospital ward up to 12 hours. Time in PACU is approximately 2 hours on average, however longer times are possible.

  3. Rate of postoperative nausea and vomiting (PONV)

    Postoperative nausea and vomiting (PONV) as determined by the recovery room nurses. Documented in the chart.

    Time frame: Postoperative. This outcome will be assess up to 12 hours after arrival in PACU.

  4. Quality of Recovery (QoR-15)

    The quality of recovery (QoR-15) questionnaire is a patient-centered measure that includes five domains of recovery after surgery: patient support, comfort, emotions, physical independence, and pain. Each item is graded on a eleven-point Likert scale with QoR-15 scores ranging from 0 (extremely poor quality of recovery) to 150 (excellent quality of recovery).

    Time frame: 3 days

  5. EuroQol five-dimensional questionnaire (EQ-5D)

    EuroQol five-dimensional questionnaire (EQ-5D) is a questionnaire used to measure health related quality of life across five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression). The EQ-5D-3L is a version of the EQ-5D that measures each dimension across three levels of severity. The EQ-5D is scored using index value set calculators to assign a numeric value where 0 is equivalent to being dead and 1 is perfect health. It is possible to have scores that are below zero indicating a state worse than being dead.

    Time frame: 3 days and 3 months

  6. Persistent postsurgical pain

    At 3 months following the procedure date, the patient will be asked about persistent post-surgical pain based on the Brief Pain Inventory (BPI). There are 7 pain interference items included in the BPI. Pain interference as measured by the BPI will be calculated by averaging the 7 pain interference items. Pain severity is measured by averaging 4 pain severity items. Each item is scored on an 11-point Likert scale from 0 to 10 such that the averages indicate no pain interference/severity at 0 and maximum pain interference/severity at 10.

    Time frame: 3 months

  7. Postoperative complications

    The following block related complications will be recorded: local anesthetic systemic toxicity, pneumothorax, bleeding, or anaphylaxis. The following adverse event data recorded in the participant's chart will be captured by the research coordinator following 7 postoperative days: pneumonia, respiratory failure, wound infection, sepsis, arrhythmias, readmission to hospital, and hospital mortality. Complications will be categorized by severity using the Clavien-Dindo (CD) classification: nonfatal complications will be defined as minor (CD level I and II) and major (CD level III and IV), and fatal complications will be categorized as CD level V. If a patient experiences more than one complication, the most severe will be used for analysis.

    Time frame: 7 days

07

Study locations

1 site
08

References and documents

Publications

  • Anger JT, Case LK, Baranowski AP, Berger A, Craft RM, Damitz LA, Gabriel R, Harrison T, Kaptein K, Lee S, Murphy AZ, Said E, Smith SA, Thomas DA, Valdes Hernandez MDC, Trasvina V, Wesselmann U, Yaksh TL. Pain mechanisms in the transgender individual: a review. Front Pain Res (Lausanne). 2024 Mar 27;5:1241015. doi: 10.3389/fpain.2024.1241015. eCollection 2024. PubMed 38601924 ↗
  • Singh NP, Makkar JK, Kuberan A, Guffey R, Uppal V. Efficacy of regional anesthesia techniques for postoperative analgesia in patients undergoing major oncologic breast surgeries: a systematic review and network meta-analysis of randomized controlled trials. Can J Anaesth. 2022 Apr;69(4):527-549. doi: 10.1007/s12630-021-02183-z. Epub 2022 Jan 31. PubMed 35102494 ↗
  • Katsnelson G, Brenna CTA, Giron-Arango L, Abdallah YM, Brull R. Analgesic benefits of regional anesthesia in the perioperative management of transition-related surgery: a systematic review. Reg Anesth Pain Med. 2025 May 6;50(5):441-448. doi: 10.1136/rapm-2024-105479. PubMed 38719225 ↗
  • Gran I, Kamali A, Granath F, Frisen L, Lindqvist EK, Dhejne C, Sommar P, Sackey H. Improved health-related quality of life and gender congruence after gender-affirming mastectomy-a prospective cohort study. J Sex Med. 2025 Oct 5;22(10):1882-1890. doi: 10.1093/jsxmed/qdaf203. PubMed 40795770 ↗
  • Lane M, Kirsch MJ, Sluiter EC, Svientek SR, Hamill JB, Morrison SD, Ives GC, Alman E, Gilman RH, Kuzon WM, Cederna PS, Wilkins EG. Gender Affirming Mastectomy Improves Quality of Life in Transmasculine Patients: A Single-center Prospective Study. Ann Surg. 2023 Mar 1;277(3):e725-e729. doi: 10.1097/SLA.0000000000005158. Epub 2021 Aug 13. PubMed 34387203 ↗
  • Sivakumar S, Kressel A, Mendonca R, Girshin M. Battle of the Blocks: Which Pain Management Technique Triumphs in Gender-Affirming Bilateral Mastectomies? J Clin Med Res. 2024 Jun;16(6):284-292. doi: 10.14740/jocmr5159. Epub 2024 Jun 18. PubMed 39027810 ↗
  • Jackman L, Chan C, Garvilles M, Kamran R. Outcome measurement for gender-affirming care in Canada: a systematic review. BMJ Open. 2025 Mar 12;15(3):e091135. doi: 10.1136/bmjopen-2024-091135. PubMed 40074262 ↗

Individual participant data

Plan to share: No — For protection of patient privacy

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Aug 2029, 31 months later.

Of 425 non-industry interventional studies with no phase under Acute Pain, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 23. This study's planned 31 months is above that.

Counting every sponsor, half of 431 studies reached it within 11 months; a quarter within 5 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2026
First posted
Oct 6, 2026
StartEst.
Jan 1, 2027
Primary completionEst.
Aug 1, 2029
CompletionEst.
Nov 1, 2029
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07861165
Responsible party
Jon Bailey (Anesthesiologist, Associate Professor, Nova Scotia Health Authority) — Principal investigator
First posted
Oct 6, 2026
Start date
Jan 1, 2027 (estimated)
Primary completion
Aug 1, 2029 (estimated)
Completion
Nov 1, 2029 (estimated)
Last update
Oct 6, 2026

Study contacts

Jonathan G Bailey
Contact
jon.bailey@nshealth.ca
902-473-4326‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬
Joseph Corkum
Contact
JosephP.Corkum@nshealth.ca
902-473-6316

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion